Amodiaquine Plus Artesunate Versus Lapdap Plus Artesunate in the Treatment of Uncomplicated P. Falciparum Malaria in Malawi
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT00164359 |
|
Recruitment Status :
Completed
First Posted : September 14, 2005
Last Update Posted : September 27, 2012
|
Sponsor:
Centers for Disease Control and Prevention
Collaborator:
Ministry of Health and Population, Malawi
Information provided by (Responsible Party):
Centers for Disease Control and Prevention
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
Sulfadoxine-pyrimethamine is the current first-line therapy for uncomplicated malaria in Malawi. Significant resistance of the P. falciparum malaria parasite to this drug has led to an imminent need for the government of Malawi to identify a new first-line therapy for uncomplicated malaria and to implement that new therapy as policy. This protocol is the second of two protocols whose combined purpose is to provide efficacy and side effect data on four antimalarial drug combinations that are candidates for the next first-line therapy for uncomplicated malaria in Malawi. This protocol aims to assess the acceptability and tolerability of amodiaquine in Malawi. It is a double-blind study comparing amodiaquine plus artesunate (AQ-Art, one of the candidate combination therapies) to chlorproguanil/dapsone plus artesunate (CD-Art, another of the candidate combination therapies) in persons 5 years and older, to see if there is a higher incidence of abdominal pain and/or refusal to take the therapy in the AQ-Art group. Amodiaquine was removed from the Malawian national drug registry in 1995 because of a perceived association with abdominal pain. Although no studies were conducted to substantiate this, consensus among clinicians was that patients were refusing amodiaquine with increasing frequency, citing abdominal pain as the reason, so the drug was removed from the registry. Results from this study, along with the efficacy data from the sister protocol in children under five years of age, will help guide the National Malaria Control Program of Malawi in selecting their next first-line antimalarial therapy.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Malaria, Falciparum | Drug: Amodiaquine plus artesunate Drug: chlorproguanil-dapsone plus artesunate | Phase 4 |
| Study Type : | Interventional (Clinical Trial) |
| Enrollment : | 212 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Double |
| Primary Purpose: | Treatment |
| Official Title: | A Double-blind Randomised Trial to Assess the Tolerability of Amodiaquine Plus Artesunate (AQ-Art) Versus Chlorproguanil Plus Dapsone Plus Artesunate (CDA) in the Treatment of Uncomplicated P. Falciparum Malaria in Malawi |
| Study Start Date : | April 2005 |
| Actual Primary Completion Date : | September 2005 |
| Actual Study Completion Date : | September 2005 |
Resource links provided by the National Library of Medicine
MedlinePlus related topics:
Malaria
Drug Information available for:
Dapsone
Primary Outcome Measures :
- Incidence of abdominal pain on days 1, 2, and 3 in the two treatment groups
Secondary Outcome Measures :
- Rate of adequate clinical and parasitological response at 14 days
- Rate of adequate clinical and parasitological response at 28 days
- Mean percent change in blood haemoglobin concentration between day 0 and day 28
- Incidence of adverse events other than abdominal pain during the period of observation
- Rate of Early Treatment Failure (per WHO definition)
- Rate of Late Clinical Failure (per WHO definition)
- Rate of Late Parasitological Failure (per WHO definition)
- Percent of patients with a decrease in haemoglobin concentration
- Percent of patients with a decrease in haemoglobin concentration of >= 2g/dl
- Prevalence of parasitemia on Day 2
- Prevalence of parasitemia on Day 3
- Gametocyte prevalence on Day 14
- Gametocyte prevalence on day 28
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 5 Years and older (Child, Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Age five years or older
- Axillary temperature >= 37.5 degrees Celsius
- Monoinfection with P. falciparum
- Parasitemia between 2000 and 200000 parasites/microliter
- Hemoglobin concentration >= 7g/dl
- Consent by the patient of patient's adult guardian
- Residence in the locality and willingness to attend for scheduled visits
- Negative urine pregnancy test in women age twelve years and older
Exclusion Criteria:
- Signs of severe or complicated malaria
- altered consciousness
- convulsions
- prostration (inability to sit/stand/suck/drink)
- respiratory distress or breathlessness
- jaundice
- abnormal breathing
- hemoglobinuria
- circulatory collapse
- persistent vomiting (cannot keep down liquids)
- evidence of a diagnosis other than malaria on physical examination
- presence of mixed infection
- presence of severe malnutrition (as evidenced by symmetrical edema involving at least the feet, light hair color, or cachexia)
- contraindications to the antimalarial drugs used, especially history of allergy
- history of receiving a drug with antimalarial activity in the week prior to enrollment
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00164359
Locations
| Malawi | |
| Kawale Health Center | |
| Lilongwe, Lilongwe District, Malawi | |
| Machinga District Hospital | |
| Liwonde, Machinga District, Malawi | |
| Matiki Health Center | |
| Dwangwa, Nkhotakota District, Malawi | |
Sponsors and Collaborators
Centers for Disease Control and Prevention
Ministry of Health and Population, Malawi
Investigators
| Principal Investigator: | Rachel N Bronzan, MD, MPH | Centers for Disease Control and Prevention |
| Responsible Party: | Centers for Disease Control and Prevention |
| ClinicalTrials.gov Identifier: | NCT00164359 |
| Other Study ID Numbers: |
CDC-NCID-4538 PA#04018 |
| First Posted: | September 14, 2005 Key Record Dates |
| Last Update Posted: | September 27, 2012 |
| Last Verified: | September 2012 |
Keywords provided by Centers for Disease Control and Prevention:
|
malaria, falciparum antimalarials |
Additional relevant MeSH terms:
|
Malaria Malaria, Falciparum Protozoan Infections Parasitic Diseases Artesunate Amodiaquine Dapsone Chlorproguanil Antimalarials Antiprotozoal Agents Antiparasitic Agents |
Anti-Infective Agents Antineoplastic Agents Antiviral Agents Schistosomicides Antiplatyhelmintic Agents Anthelmintics Folic Acid Antagonists Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Leprostatic Agents Anti-Bacterial Agents |